The experts discuss efficacy of SGLT2
inhibitors in patients with CKDm, safety of SGLIT2 inhibtiors in patients with
CKD, comparative effects of SGLT2i in those with/without type 2 diabetes, efficacy
of new agents tested in recent trials for patients with CKD, and safety
of new agents tested in recent trials for patients with CKD.
